AGREE I | AGREE II | Change from AGREE I to AGREE II | ||||
---|---|---|---|---|---|---|
Domain | No | Item | Item | No | Domain | |
1. Scope and purpose | 1 | The overall objective(s) of the guideline is (are) specifically described | The overall objective(s) of the guideline is (are) specifically described | 1 | 1. Scope and purpose | No change |
2 | The clinical question(s) covered by the guideline is (are) specifically described | The health question(s) covered by the guideline is (are) specifically described | 2 | Change in underline part | ||
3 | The patients to whom the guideline is meant to apply are specifically described | The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described | 3 | Change in underline part | ||
2. Stakeholder involvement | 4 | The guideline development group includes individuals from all the relevant professional groups | The guideline development group includes individuals from all the relevant professional groups | 4 | 2. Stakeholder involvement | No change |
5 | The patients’ views and preferences have been sought | The views and preferences of the target population (patients, public, etc.) have been sought | 5 | Change in underline part | ||
6 | The target users of the guideline are clearly defined. No | The target users of the guideline are clearly defined. No | 6 | No change | ||
7 | The guideline has been piloted among end users | Delete item. Incorporated into user guide description of item 19 | ||||
3. Rigour of development | 8 | Systematic methods were used to search for evidence | Systematic methods were used to search for evidence | 7 | 3. Rigour of development | No change, renumber to 7 |
9 | The criteria for selecting the evidence are clearly described | The criteria for selecting the evidence are clearly described | 8 | No change, renumber to 8 | ||
The strengths and limitations of the body of evidence are clearly described | 9 | New item | ||||
10 | The methods for formulating the recommendations are clearly described | The methods for formulating the recommendations are clearly described | 10 | No change | ||
11 | The health benefits, side effects, and risks have been considered in formulating the recommendations | The health benefits, side effects, and risks have been considered in formulating the recommendations | 11 | No change | ||
12 | There is an explicit link between the recommendations and the supporting evidence | There is an explicit link between the recommendations and the supporting evidence | 12 | No change | ||
13 | The guideline has been externally reviewed by experts prior to its publication | The guideline has been externally reviewed by experts prior to its publication | 13 | No change | ||
14 | A procedure for updating the guideline is provided | A procedure for updating the guideline is provided | 14 | No change | ||
4. Clarity of presentation | 15 | The recommendations are specific and unambiguous | The recommendations are specific and unambiguous | 15 | 4. Clarity of presentation | No change |
16 | The different options for management of the condition are clearly presented | The different options for management of the condition or health issue are clearly presented | 16 | Change in underline part | ||
17 | Key recommendations are easily identifiable | Key recommendations are easily identifiable | 17 | No change | ||
18 | The guideline is supported with tools for application | The guideline describes facilitators and barriers to its application | 19 | 5. Applicability | Change in underline part, renumber to 19, change in domain from #4 clarity of presentation to #5 applicability | |
5. Applicability | 19 | The potential organizational barriers in applying the recommendations have been discussed | The guideline provides advice and/or tools on how the recommendations can be put into practice | 18 | Change in underline part, renumber to 18. | |
20 | The potential cost implications of applying the recommendations have been considered | The potential resource implications of applying the recommendations have been considered | 20 | Change in underline part | ||
21 | The guideline presents key review criteria for monitoring and/ or audit purposes | The guideline presents monitoring and/ or auditing criteria | 21 | Change in underline part | ||
6. Editorial independence | 22 | The guideline is editorially independent from the funding body | The views of the funding body have not influenced the content of the guideline | 22 | 6. Editorial independence | Change in underline part |
23 | Conflicts of interest of guideline development members have been recorded | Competing interests of guideline development group members have been recorded and addressed | 23 | Change in underline part | ||
Overall guideline assessment | Rate the overall quality of this guideline | 1 | Overall guideline assessment | New item | ||
1 | I would recommend this guideline for use | I would recommend this guideline for use | 2 | Renumber to 2 |